Abstract:The ongoing Pandemic Agreement negotiations illustrate significant gaps in action required to respond effectively to the lessons of the COVID-19 pandemic and make progress towards public health goals, including Sustainable Development Goals (SDGs). The pandemic revealed vaccine equity as a unifying health need, and international trade as a Commercial Determinant of Health. We explored where policy action could reshape trade relationships, identifying recommendations for vaccine equity within stakeholder literature pertaining to Free Trade Agreements (FTAs). We searched online libraries for stakeholder documents that focused on the interface between FTAs, vaccination, and vaccine equity published between 01/01/2010-31/03/2022. Our analytic framework drew from the rights, regulation, and redistribution (3R) framework, combined with systems analysis, using leverage pointsto categorise recommendations as Technical Mechanisms, Collaborative and Adaptive Mechanisms, or Determinants of Vaccine Equity (DVE). These were then located on a novel systems map to elucidate gaps and actions. No cohesive strategies for change were identified. Technical proposals were reactive, repetitive, and lacked enforcement mechanisms or incentives. There were significant gaps in the articulation of alternative Collaborative Mechanisms to democratise FTA policymaking processes. The underlying DVE and lack of policy coherence were not addressed. These findings are limited by under-representation of low- and middle-income country authorship in the studies, including in ours, reflecting imbalances in international research and policymaking processes. Overall, our research shows how the current trade paradigm has produced and sustained vaccine inequity. We propose potential pathways for action but highlight the importance and urgency of more fundamental change in negotiation and implementation of FTAs. New technologies will be crucial for the global response to emerging, neglected, and non-communicable diseases that are vaccine-preventable or -modifiable. Multilateral organisations must, therefore, prioritise the right to health above FTAs , including through TRIPS waivers on Essential Technologies.

Equity in the Pandemic Treaty: Access and Benefit-Sharing as a Policy Device or a Rhetorical Device?

The importance of getting the ethics right in a pandemic treaty

Transforming trade for vaccine equity: policy gaps and barriers

Study on major legal issues and solutions in pandemic treaty negotiations

The Pandemic Treaty, the Pandemic Fund, and the Global Commons: our scepticism

Underlying Equity Discourses of the World Health Organization

A pandemic agreement is within reach

The pandemic treaty: a grand global social bargain

Equitable Pandemic Preparedness and Rapid Response: Lessons from COVID-19 for Pandemic Health Equity

Pandemic preparedness and response: a new mechanism for expanding access to essential countermeasures

China and the WHO pandemic treaty: a dive into stance, underpinnings, and implications

Increasing compliance with international pandemic law: international relations and new global health agreements

Scoping review of the World Health Organization’s underlying equity discourses: apparent ambiguities, inadequacy, and contradictions

Global inequities in access to COVID-19 health products and technologies: A political economy analysis

Law and Policy as Tools in Healthy People 2030

Access to COVID-19 Vaccines: A New Global Approach

Pandemic treaty as an instrument to strengthen global health security: Global health diplomacy at its crux

Exploiting treaty ambiguity: Public health exceptions in the WTO TRIPS agreement

Rifts over equity imperil WHO's pandemic treaty

A global pandemic treaty is in sight: don't scupper it

Pandemic inequalities: emerging infectious diseases and health equity